Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gigi A Moreno"'
Publikováno v:
Forum for health economicspolicy. 20(2)
Price controls for prescription drugs are once again at the forefront of policy discussions in the United States. Much of the focus has been on the potential short-term savings – in terms of lower spending – although evidence suggests price contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac4baaf75d719aee99087f855a31e81
https://pubmed.ncbi.nlm.nih.gov/31419906
https://pubmed.ncbi.nlm.nih.gov/31419906
Autor:
Diana K. Vania, Yuri Sanchez Gonzalez, Gigi A Moreno, Brian R. Edlin, Ron Brookmeyer, Oliver Díaz Espinosa, Alice Wang
Publikováno v:
Value in Health.
Objectives The objective of this study was to explore the trade-offs society and payers make when expanding treatment access to patients with chronic hepatitis C virus (HCV) infection in early stages of disease as well as to vulnerable, high-risk pop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c1d393b1860b5b0d187f69b27a874d
Autor:
Mark T, Linthicum, Yuri Sanchez, Gonzalez, Karen, Mulligan, Gigi A, Moreno, David, Dreyfus, Timothy, Juday, Steven E, Marx, Darius N, Lakdawalla, Brian R, Edlin, Ron, Brookmeyer
Publikováno v:
The American journal of managed care. 22(6 Spec)
To investigate the value of expanding screening and treatment for hepatitis C virus (HCV) infection in the United States.Discrete-time Markov model.We modeled HCV progression and transmission to analyze the costs and benefits of investment in screeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0753144249bfb8300007a837b67a1e3c
https://pubmed.ncbi.nlm.nih.gov/27266953
https://pubmed.ncbi.nlm.nih.gov/27266953
Autor:
Gigi A, Moreno, Karen, Mulligan, Caroline, Huber, Mark T, Linthicum, David, Dreyfus, Timothy, Juday, Steven E, Marx, Yuri Sanchez, Gonzalez, Ron, Brookmeyer, Darius N, Lakdawalla
Publikováno v:
The American journal of managed care. 22(6 Spec)
Hepatitis C virus (HCV) treatment incentives for private payers may be misaligned because payers must bear immediate costs and may not realize long-term benefits. However, these benefits may accrue to future payers, including Medicare. We examined ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0834874353943a54223d1518f704a849
https://pubmed.ncbi.nlm.nih.gov/27266954
https://pubmed.ncbi.nlm.nih.gov/27266954